Large Area Microfluidic Bioreactor for Production of Recombinant Protein

Biosensors (Basel). 2022 Jul 14;12(7):526. doi: 10.3390/bios12070526.

Abstract

To produce innovative biopharmaceuticals, highly flexible, adaptable, robust, and affordable bioprocess platforms for bioreactors are essential. In this article, we describe the development of a large-area microfluidic bioreactor (LM bioreactor) for mammalian cell culture that works at laminar flow and perfusion conditions. The 184 cm2 32 cisterns LM bioreactor is the largest polydimethylsiloxane (PDMS) microfluidic device fabricated by photopolymer flexographic master mold methodology, reaching a final volume of 2.8 mL. The LM bioreactor was connected to a syringe pump system for culture media perfusion, and the cells' culture was monitored by photomicrograph imaging. CHO-ahIFN-α2b adherent cell line expressing the anti-hIFN-a2b recombinant scFv-Fc monoclonal antibody (mAb) for the treatment of systemic lupus erythematosus were cultured on the LM bioreactor. Cell culture and mAb production in the LM bioreactor could be sustained for 18 days. Moreover, the anti-hIFN-a2b produced in the LM bioreactor showed higher affinity and neutralizing antiproliferative activity compared to those mAbs produced in the control condition. We demonstrate for the first-time, a large area microfluidic bioreactor for mammalian cell culture that enables a controlled microenvironment suitable for the development of high-quality biologics with potential for therapeutic use.

Keywords: anti-hIFN-α2b; antibody activity; cell culture; large-area; microfluidic bioreactor; monoclonal antibody.

MeSH terms

  • Animals
  • Antibodies, Monoclonal
  • Bioreactors*
  • CHO Cells
  • Cell Culture Techniques / methods
  • Cricetinae
  • Cricetulus
  • Microfluidics*
  • Recombinant Proteins

Substances

  • Antibodies, Monoclonal
  • Recombinant Proteins